CSPC Pharmaceutical Group (HK:1093) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for its new long-acting semaglutide injection, SYH9017. This innovative product aims to improve patient adherence by extending dosing to once a month for weight management in overweight or obese adults. The approval marks a significant step for CSPC’s development of long-acting GLP-1 receptor agonists, with potential additional benefits for type 2 diabetes and cardiovascular risk reduction.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
